Results 131 to 140 of about 23,901 (228)
Severe Hypocalcemia After Denosumab Treatment Leading to Refractory Ventricular Tachycardia
Description: Case Report: A 70-year-old man with multiple myeloma developed severe hypocalcemia 1 week after receiving denosumab. Despite calcium supplementation, he developed refractory ventricular tachycardia.
Baral, Bidisha +2 more
core +1 more source
Iron and Other Metal Ions in Human Health and Disease
MedComm, Volume 7, Issue 10, October 2026.Iron, copper, zinc, and calcium orchestrate cellular function through distinct yet cooperative mechanisms: redox‐active iron and copper cycle between oxidation states to act as Fenton catalysts and electron carriers in oxidative phosphorylation (OXPHOS); redox‐inert zinc serves as a structural component of zinc‐finger proteins and a catalytic cofactor ...
Xiaofeng Dai, Jitian Li
wiley +1 more source
Giant-cell tumor of bone: treatment options and role of denosumab
, 2015 Arun S Singh,1 Neal S Chawla,2 Sant P Chawla2 1Sarcoma Service, Division of Hematology/Oncology, University of California, Los Angeles, 2Sarcoma Oncology Center, Santa Monica, CA, USA Abstract: Giant-cell tumor of bone is a rare, locally aggressive ...
Chawla SP, Singh AS, Chawla NS
core
Mind the Gap: Predictors of Osteoporosis Treatment Following Fragility Fracture in Parkinsonism
Movement Disorders Clinical Practice, Volume 13, Issue 10, Page 2474-2499, October 2026.Abstract Background Fracture risk is increased in Parkinson's yet this risk is often not addressed. Objectives Our objective was to study the extent to which osteoporosis was treated, and predictors of treatment in a large representative cohort with parkinsonism.
Katie C. Naylor +2 more
wiley +1 more source
Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics
, 2015 Denosumab, a monoclonal antibody against the receptor activator for nuclear factor-kappa B ligand (RANKL), is a recently approved antiresorptive drug that suppresses osteoclast formation by targeting preosteclasts, in contrast to the traditional ...
이강희, 박원서
core +1 more source
Clinical Transplantation, Volume 40, Issue 10, October 2026.ABSTRACT Background Bone loss and fractures are critical post‐kidney transplantation (KT) complications. We evaluated age‐stratified screening practices, treatment patterns, and fracture incidence in a nationwide KT cohort. Methods Using the Korean National Health Insurance Service database (2003–2020), we analyzed 34 758 adult KT recipients. Screening
Ji Eun Kim +7 more
wiley +1 more source
Chinese Guideline on Risk Management of Osteoporosis in the General Public
Orthopaedic Surgery, Volume 18, Issue 10, Page 2015-2031, October 2026.Summary of the background, key recommendations, and expected impact of the public guideline for osteoporosis risk management. ABSTRACT Background Osteoporosis is a common chronic skeletal disorder characterized by decreased bone mass and microarchitectural deterioration, resulting in increased fragility and fracture risk. With rapid population aging in
Shiyong Zhang +84 more
wiley +1 more source
, 2018 Masashi Uehara,1 Yukio Nakamura,1 Jun Takahashi,1 Mikio Kamimura,2 Fumihiro Isobe,1 Tomomi Yamaguchi,3,4 Tomoki Kosho,3,4 Shigeharu Uchiyama,1,5 Takako Suzuki,1 Hiroyuki Kato1 1Department of Orthopedic Surgery, Shinshu University School of Medicine ...
Kamimura M +9 more
core
This study’s objective was to demonstrate pharmacokinetic (PK) similarity and safety of denosumab biosimilar, CT‑P41, and United States–licensed reference denosumab (US-denosumab) in healthy male Asian adults, considering also pharmacodynamic (PD ...
Anhye Kim (2849126) +11 more
core +2 more sources
Denosumab Treatment of Severe Disuse Osteoporosis in a Boy With Spinal Muscular Atrophy
Acta Medica Iranica, 2017 Denosumab is a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand. Denosumab is used in the treatment of postmenopausal osteoporosis and cancer-related bone disorders.
Stepan Kutilek
doaj